Q-omics provides the consensus-scored RPS29P22 profile across patient tissues and cancer cell-line models. RPS29P22 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPS29P22 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RPS29P22 RNA expression shows 10,361 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, HNSC, and GBM as cancer lineages where RPS29P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P22 survival associations across molecular data types. RPS29P22 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P22 RNA expression–survival associations across cancer types. High RPS29P22 expression shows unfavorable associations in STAD, CHOL, ACC and TGCT, but favorable associations in BLCA and READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RPS29P22 RNA expression.
This table summarizes RPS29P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P22 shows lower tumor expression in KIRC and higher tumor expression in HNSC, CHOL, BRCA and BLCA. The HNSC box plot shows higher RPS29P22 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p = .004).
This table shows molecular features associated with RPS29P22 in patient tissues and cancer cell lines. In patient samples, RPS29P22 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
